Diabetes - Pipeline Insight, 2025
Description
DelveInsight’s, “Diabetes - Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetes: Overview
Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to the body's inability to produce or effectively use insulin, a hormone essential for regulating glucose. The disease primarily exists in two main forms: Type 1 diabetes, an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas, and Type 2 diabetes, which is more common and often associated with insulin resistance and lifestyle factors such as obesity and poor diet. Other types include gestational diabetes, which occurs during pregnancy, and rarer forms such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).
The signs and symptoms of diabetes can vary depending on the type and severity of the condition but generally include increased thirst and frequent urination, as the body tries to flush out excess glucose from the blood. Other common symptoms are extreme hunger, unexpected weight loss, fatigue, and blurred vision due to fluctuating blood sugar levels. Slow-healing sores, frequent infections, and tingling or numbness in the hands and feet are also prevalent, particularly in Type 2 diabetes, indicating nerve damage.
The pathophysiology of diabetes involves disruptions in the body's ability to regulate blood glucose, primarily due to issues with insulin production or function. In Type 1 diabetes, an autoimmune response mistakenly targets and destroys the insulin-producing beta cells in the pancreas, leading to little or no insulin production. Without insulin, glucose cannot enter cells for energy, resulting in elevated blood sugar levels. In Type 2 diabetes, the body’s cells become resistant to insulin, and the pancreas fails to produce enough insulin to compensate for this resistance. This leads to a gradual rise in blood glucose levels. Chronic hyperglycemia associated with both types of diabetes causes damage to blood vessels, nerves, and various organs over time, contributing to complications like cardiovascular disease, neuropathy, retinopathy, and nephropathy. The interplay of genetic, environmental, and lifestyle factors further influences the onset and progression of both forms of the disease.
The treatment of diabetes focuses on managing blood sugar levels through a combination of lifestyle changes, medication, and monitoring to prevent complications. For Type 1 diabetes, insulin therapy is essential since the body cannot produce insulin, and this can be administered via injections or an insulin pump. Type 2 diabetes management often begins with lifestyle modifications, including a balanced diet, regular physical activity, and weight loss, which can improve insulin sensitivity. If these measures are insufficient, oral medications like metformin or other drugs that increase insulin production or improve its effectiveness may be prescribed.
""Diabetes- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetes pipeline landscape is provided which includes the disease overview and Diabetes treatment guidelines. The assessment part of the report embraces, in depth Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetes Emerging Drugs
Further product details are provided in the report……..
Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetes drugs.
Diabetes Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Diabetes: Overview
Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to the body's inability to produce or effectively use insulin, a hormone essential for regulating glucose. The disease primarily exists in two main forms: Type 1 diabetes, an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas, and Type 2 diabetes, which is more common and often associated with insulin resistance and lifestyle factors such as obesity and poor diet. Other types include gestational diabetes, which occurs during pregnancy, and rarer forms such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).
The signs and symptoms of diabetes can vary depending on the type and severity of the condition but generally include increased thirst and frequent urination, as the body tries to flush out excess glucose from the blood. Other common symptoms are extreme hunger, unexpected weight loss, fatigue, and blurred vision due to fluctuating blood sugar levels. Slow-healing sores, frequent infections, and tingling or numbness in the hands and feet are also prevalent, particularly in Type 2 diabetes, indicating nerve damage.
The pathophysiology of diabetes involves disruptions in the body's ability to regulate blood glucose, primarily due to issues with insulin production or function. In Type 1 diabetes, an autoimmune response mistakenly targets and destroys the insulin-producing beta cells in the pancreas, leading to little or no insulin production. Without insulin, glucose cannot enter cells for energy, resulting in elevated blood sugar levels. In Type 2 diabetes, the body’s cells become resistant to insulin, and the pancreas fails to produce enough insulin to compensate for this resistance. This leads to a gradual rise in blood glucose levels. Chronic hyperglycemia associated with both types of diabetes causes damage to blood vessels, nerves, and various organs over time, contributing to complications like cardiovascular disease, neuropathy, retinopathy, and nephropathy. The interplay of genetic, environmental, and lifestyle factors further influences the onset and progression of both forms of the disease.
The treatment of diabetes focuses on managing blood sugar levels through a combination of lifestyle changes, medication, and monitoring to prevent complications. For Type 1 diabetes, insulin therapy is essential since the body cannot produce insulin, and this can be administered via injections or an insulin pump. Type 2 diabetes management often begins with lifestyle modifications, including a balanced diet, regular physical activity, and weight loss, which can improve insulin sensitivity. If these measures are insufficient, oral medications like metformin or other drugs that increase insulin production or improve its effectiveness may be prescribed.
""Diabetes- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetes pipeline landscape is provided which includes the disease overview and Diabetes treatment guidelines. The assessment part of the report embraces, in depth Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Diabetes.
This segment of the Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetes Emerging Drugs
- Cadisegliatin: vTv Therapeutics
- LY-3209590: Eli Lilly and Company
- THDB0206: Tonghua Dongbao Pharmaceutical
- CPL207280: Celon Pharma
- XW014: Sciwind Biosciences
- KN056: Suzhou Alphamab Co., Ltd.
Further product details are provided in the report……..
Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetes
- There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. Phase III include, vTv Therapeutics, Eli Lilly and Company and Tonghua Dongbao Pharmaceutical.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetes drugs.
Diabetes Report Insights
- Diabetes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetes drugs?
- How many Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
- vTv Therapeutics
- Tonghua Dongbao Pharmaceutical
- Eli Lilly and Company
- Celon Pharma
- Sciwind Biosciences
- AstraZeneca
- Suzhou Alphamab Co., Ltd.
- Neurodon
- Abarceo Pharma
- Chong Kun Dang Pharmaceutical
- Cadisegliatin
- THDB0206
- LY-3209590
- CPL207280
- XW014
- ECC5004
- KN056
- RGT001-075
- NRDN-101
- Research programme: Diabetes mellitus therapeutics
- CKD-383
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Table of Contents
450 Pages
- Introduction
- Executive Summary
- Diabetes: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetes– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Cadisegliatin: vTv Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- CPL207280: Celon Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- KN056: Suzhou Alphamab Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetes Key Companies
- Diabetes Key Products
- Diabetes- Unmet Needs
- Diabetes- Market Drivers and Barriers
- Diabetes- Future Perspectives and Conclusion
- Diabetes Analyst Views
- Diabetes Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
